# Efferon
> Company in Tuttlingen, Germany.

- Canonical entity: https://directory.readyscan.ai/entities/efferon-q137943996
- Website listed in the source snapshot: https://efferon.com/
- Category: [Businesses](https://directory.readyscan.ai/directory/businesses)
- Machine record: https://directory.readyscan.ai/discovery/entities/efferon-q137943996.json
- Material fingerprint: fnv1a64:75cfedd9d22f2670
- Entity revision: fnv1a64:e453538828131d86
- Published: 2026-10-24
- Modified: 2026-10-24

## Questions & answers
### [What is sepsis?](https://directory.readyscan.ai/entities/efferon-q137943996#company-answer-content-native-digital-agencies-dc403383994e1b29-a-6539a10d54fcbd916be7)
“Sepsis is the body's life-threatening response to infection, in which the immune system damages its own tissues and organs while fighting the infection. If left untreated, sepsis can progress to septic shock and multiple organ failure. Globally, sepsis is implicated in nearly one in five deaths, with roughly 48.9 million cases and 11 million deaths each year.”
Sources: https://efferon.com/indications/

### [What is hemoadsorption and how does Efferon technology work?](https://directory.readyscan.ai/entities/efferon-q137943996#company-answer-content-native-digital-agencies-dc403383994e1b29-a-cb22df4ff4ac8bb01c5f)
“Hemoadsorption is an extracorporeal blood purification technique that passes a patient's blood through a cartridge containing an adsorbent that selectively binds harmful molecules. Efferon devices use a proprietary multimodal adsorbent that simultaneously removes endotoxin (LPS) and inflammatory cytokines, the two main drivers of systemic inflammation in sepsis and septic shock.”
Sources: https://efferon.com/indications/

### [Is Efferon NEO approved for use in children?](https://directory.readyscan.ai/entities/efferon-q137943996#company-answer-content-native-digital-agencies-dc403383994e1b29-a-0a0debd153c0a2564ffe)
“Yes. Efferon NEO received the CE MDR mark in April 2026 and is the first multimodal extracorporeal blood purification device specifically approved in Europe for pediatric patients with sepsis and septic shock from 1 month of age. In the multicenter LASSO NEO trial (NCT05707494) Efferon NEO significantly reduced 28-day mortality (9% versus 35% in controls).”
Sources: https://efferon.com/indications/

## Company sources
- [Efferon website](https://efferon.com/) — efferon.com
- [efferon.com/indications/](https://efferon.com/indications/) — efferon.com · [Related Ready Scan knowledge](https://readyscan.ai/sources/source-0841ec68f75944f1)
- [wikidata.org/wiki/Special:EntityData/Q137943996.json](https://www.wikidata.org/wiki/Special:EntityData/Q137943996.json?revision=2459371700) — wikidata.org · [Related Ready Scan knowledge](https://readyscan.ai/sources/source-8fad253317455727)

## Continue reading
- Discover the bounded graph: https://readyscan.ai/api/v1/ai-search/discovery
- Retrieve this entity evidence: https://readyscan.ai/api/v1/ai-search/entities/efferon-q137943996/evidence

## Publication boundary
- This public-sourced record brings together company information and its sources. It is not an owner-managed profile.
- Publication does not guarantee crawling, indexing, training inclusion, citation, recommendation, referral, or revenue.